COG # AREN0532
Treatment for Very Low and Standard Risk Favorable Histology Wilms Tumor Study
This study is for patients with Stage I-III favorable histology Wilms tumor determined by clinical & biological risk factors. This study will have three strata: very low risk patients treated with surgery and observation alone, standard risk patients with
LOH treated with chemotherapy alone and standard risk patients with out LOH treated with the same chemotherapy but also adding radiotherapy.
- All patients must be enrolled on the AREN03B2 Renal Tumor Biology and Classification Study before enrolling on this study and be found to have newly diagnosed Stage I-III favorable histology Wilms tumor, confirmed by central pathology, surgical and radiology review
- Patients must be less than 30 years old at the time of initial diagnosis.
- Patients must have adequate liver, and cardiac function as defined in the protocol.
Mandy Atkinson, M.D.
Wendy McCarty, Research Coordinator